Bionure and Myelin Repair Foundation will collaborate to advance a therapy for multiple sclerosis

The Myelin Repair Foundation and Bionure have entered a collaborative partnership agreement to advance therapeutics development for Multiple Sclerosis. In this agreement, the Myelin Repair Foundation will work closely with Bionure, Inc. to assess the neuroprotective capabilities that will promote myelin repair of the company's proprietary MS therapeutic compound, BN201. The main objective is to advance promising compounds into the clinic. Bionure is a Silicon Valley and Barcelona based early stage drug development company focused on developing neuroprotective therapies for the treatment of neurodegenerative diseases. It is a Spin-Off company based on a Hospital Clínic – IDIBAPS – CSIC research, which was started by Dr. Pablo Villoslada, investigator at the IDIBAPS team Clinical and experimental neuroimmunology.